BioAgilytix provides the specialized large molecule insight and proven GLP / GMP knowledge needed to support a full range of cell-based assay requirements. Our veteran team possesses expertise with primary cells and transformed cell lines. Working with our customers, we are able to develop and validate custom cell-based assays in line with all relevant regulatory guidelines and recommendations.
Find Answers to Your Cell-Based Assay Questions:
What are your specific assay needs? Let’s schedule a conversation to review your questions and requirements with one of our scientists.
Cell-based assays can be used to evaluate a variety of functional and biochemical effects, including cell proliferation, apoptosis and cell death, signal transduction, enzyme activity, reporter gene activity, antibody (ADCC) and complement dependent (CDC) cytoxicity, among others. These techniques are used to support neutralizing antibody (NAb) assays, relative potency assays, mechanism of action studies and drug combination analysis, to name a few.
Because live cells are used, cell-based assays provide a functional read-out of compound activity, or produce results that are more biologically relevant or have physiological relevance.
View Our Virtual Podium:
In this Virtual Podium video, Dr. David Rusnak of BioAgilytix offers his expert insight for evaluating the optimal cell-based model system.
The complexity involved in live cell analysis demands an advanced level of bioanalytical skill and knowledge – not just for the assay itself, but for the regulatory parameters that assay must uphold. With our scientific staff averaging 15+ years of experience developing and performing cell-based assays, BioAgilytix is uniquely qualified in this capacity.
Our team has vast experience with primary cells and transfected reporter-gene cell systems, and can develop and validate cell-based assays under GLP, GCP, and GMP. In fact, our scientists were responsible for lead optimization and mechanism-of-action studies that led to the discovery a several key drugs that are on the market today, as well as a number of promising clinical candidates.
There are numerous opportunities to utilize cell-based assays in support of the development of biologic breakthroughs.
Cell-based assays can be used for cell proliferation studies assessing cell number increases resulting from cell growth and division.
Cell-based assays are also used to analyze cell cycle machinery and signaling pathways that control cell arrest and programmed cell death.
Aiding in the understanding cellular activities and coordination, cell-based assays can be used to assess errors in cellular information processing, and provide insight into how to effectively treat the diseases caused by those errors.
BioAgilytix offers a diverse range of innovative platforms for cell-based assay work as part of our premier laboratory facility. We are able to provide multiplexing of our readouts and apply automation for increased assay throughput and reproducibility. Our scientists will help you choose the method to optimally support your distinct cell-based assay parameters, leveraging the range of platforms listed below.
BioAgilytix provides robust cell-based assay services to support drug development through all phases of a product’s lifecycle, from pre-clinical and clinical phases to lot release testing and post-marketing surveillance.
Whether performing ADCC and CDC assays, reporter gene assays, cutpoint and outlier statistical analysis, or drug combination analysis, we can tailor our cell-based assay services to meet your specific level of regulatory requirement. We are a specialized GLP / GMP compliant bioanalytical lab offering a unique combination of veteran expertise, premier lab facilities, and deep regulatory know-how, which we fully leverage in helping our customers compress their timeline from discovery to market.
Let us help you navigate the path to biologic innovation with expert cell-based assay services.
Our Cell-Based Assay Expertise Includes:
See how we employ world-leading immunogenicity expertise to measure adverse immune reactions for many drug- and disease-specific aspects.
Learn how we will translate our experience working with over 500 biomarkers in singleplex and multiplex formats to your project’s success.